AbbVie wins FDA approval for Parkinson's pill tavapadon as Juvmo
🤖 AI-generated content — The title and summary were produced automatically by artificial intelligence, without human editorial review.
The FDA approved AbbVie's once-daily Parkinson's pill tavapadon, branded as Juvmo, following a late-stage study. Meanwhile, Novo Nordisk is increasingly marketing Wegovy for direct-to-consumer weight loss rather than chronic obesity treatment, with cash-paying patients spending up to $450 monthly, raising equity concerns among clinicians.
Continue in the app — vote & join in ➔Source: STAT News · via ahirlevel.hu